Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allograftingMarcello Rotta, David G. Maloney, Barry E. Storer et al.|Blood|2008Cited by 105
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysisJoseph A. Pidala, Samantha Jaglowski, Jongphil Kim et al.|Blood Advances|2024Cited by 16
Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007Ghayas C. Issa, Eunice S. Wang, James McCloskey et al.|Blood|2025Cited by 7
AML-732: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Eunice S. Wang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 3
Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).Marcello Rotta, David G. Maloney, Barry E. Storer et al.|Blood|2007Cited by 3